The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples